We examined the combinatory antitumor effects of adenoviruses expressing human mda-7/IL-24 gene (Ad-mda-7) and chemotherapeutic agents on nine kinds of human esophageal carcinoma cells. All the carcinoma cells expressed the melanoma differentiation-associated gene-7/interleukin-24 (MDA-7/IL-24) receptor complexes, IL-20R2 and either IL-20R1 or IL-22R1, and were susceptible to Ad-mda-7, whereas fibroblasts were positive only for IL-20R2 gene and resistant to Ad-mda-7-mediated cytotoxicity. Sensitivity of these esophageal carcinoma cells to Ad-mda-7 was however lower than that to Ad expressing the wild-type p53 gene. We thereby investigated a possible combination of Ad-mda-7 and anticancer agents and found that Ad-mda-7 with 5-fluorouracil (5-FU), cisplatin, mitomycin C or etoposide produced greater cytotoxic effects than those by Ad-mda-7 or the agent alone. Halfmaximal inhibitory concentration values of the agents in respective cells were decreased by the combination with Ad-mda-7. Cell cycle analyses showed that Ad-mda-7 and 5-FU increased G2/M-phase and S-phase populations, respectively, and the combination augmented sub-G1 populations. Ad-mda-7-treated cells showed cleavages of caspase-8, -9 and -3 and poly (ADP-ribose) polymerase, but the cleavage levels were not different from those of the combination-treated cells. Ad-mda-7 treatments upregulated Akt phosphorylation but suppressed IkB-a levels, whereas 5-FU treatments induced phosphorylation of p53 and extracellular signal-regulated protein kinases 1 and 2. Molecular changes caused by the combination were similar to those by Admda-7 treatments, but the Ad-mda-7-mediated upregulation of Akt phosphorylation decreased with the combination. These data collectively suggest that Ad-mda-7 induced apoptosis despite Akt activation and that the combinatory antitumor effects with 5-FU were produced partly by downregulating the Ad-mda-7-induced Akt activation.
INTRODUCTION
Esophageal carcinoma develops in aged individuals and surgical procedures often decrease the quality of life of the patient. Esophageal carcinoma in general responds to chemotherapy and radiotherapy but further improvement of the prognosis is desirable. 1 Expression of a cytotoxicity-inducing gene in tumors is a novel strategy and adenovirus (Ad)-mediated gene transfer has been investigated for the antitumor effects at preclinical and clinical levels. We demonstrated efficacy and safety of Ad expressing the wild-type p53 gene (Ad-p53) to esophageal carcinoma at a preclinical level and in a phase I/II clinical study. 2, 3 These studies indicated that transduction of esophageal carcinoma with an apoptosis-inducing gene was a possible therapeutic strategy.
Forced expression of human melanoma differentiation-associated gene-7 (MDA-7), also known as interleukin (IL)-24, induced cell death and Ad bearing the mda-7 gene (Ad-mda-7) produced antitumor effects to a number of human tumors. 4 Ad-mda-7-mediated cytotoxicity was attributable to various mechanisms including endoplasmic stresses-induced apoptosis, autophagy, antiangiogenesis and perhaps immune stimulations. 5 Nevertheless, the cytotoxic effects have not been well studied in squamous cell carcinoma and it remains yet unknown whether Ad-mda-7 induced cytotoxicity in esophageal carcinoma. Ligation of MDA-7 and the MDA-7/IL-24 receptor complexes, the heterodimeric structures consisting of IL-20R1/IL-20R2 or IL-22R1/IL-20R2, was crucial for cell death induction, 6 and activated multiple downstream pathways as demonstrated with subcellular compartmenttargeted Ad-mda-7. 7 Previous studies also showed that Ad-mda-7 were less effective in producing antitumor effects in some tumor types such as pancreatic carcinoma, 8 although the mechanisms underlying resistance were not fully understood. A combinatory use of chemotherapeutic agents is one of the strategies to enhance the cytotoxic effects of Ad-mda-7 and overcome such resistant cases that, in turn, also circumvents adverse effects by the agents with supplementary MDA-7-mediated cytotoxicity. In this study, we examined the antitumor effects of Ad-mda-7 on a panel of human esophageal squamous cell carcinoma and found that these cells were relatively resistant to cell death induced by 1 Ad-mda-7 in comparison with Ad-p53. We then further tested the combinatory effects of Ad-mda-7 and chemotherapeutic agents, 5-fluorouracil (5-FU), cisplatin (CDDP), mitomycin C (MMC) and etoposide (VP-16), some of which are commonly used for esophageal carcinoma treatments.
MATERIALS AND METHODS

Cells and anticancer reagents
Human esophageal carcinoma, TE-1, TE-2, TE-10, TE-11 YES-2, YES-4, YES-5, YES-6 and T.Tn cells, human lung carcinoma, A549 cells, and human fibroblasts, OUMS-24 (ref. 9) and HFF 10 cells, were cultured with RPMI-1640 medium supplemented with 10% fetal calf serum. Anticancer agents, 5-FU (Wako, Osaka, Japan), CDDP (Wako), MMC (Wako) and VP-16 (SigmaAldrich St Louis, MO, USA) were dissolved with dimethyl sulfoxide or phosphate-buffered saline. The p53 status of esophageal carcinoma cells is shown in Table 1 .
Ad preparation
Replication-incompetent Ad-mda-7, Ad-p53 and Ad expressing the b-galactosidase gene (Ad-LacZ) were prepared with an Adeno-X expression system (Takara, Shiga, Japan) and purified with an Adeno-X virus purification kit (BD Biosciences, San Jose, CA, USA). These Ad vectors used the same cytomegalovirus promoter to activate the respective genes. The numbers of virus particles (vp) per ml was estimated with the formula: absorbance at 260 nm of purified Ad in the presence of 0.1% sodium dodecyl sulfate Â 1.1 Â 10 12 .
Reverse transcription-PCR In vitro cytotoxicity Cells (5 Â 10 3 per well) were seeded in 96-well plates and were cultured for 5 days with different amounts of Ad (vp per cell) and/or various concentrations of anticancer agents. Cell viability was determined with a cell-counting WST kit (Wako). The amount of formazan produced in each well was determined with the absorbance at 450 nm and the relative viability was calculated based on the absorbance without any treatments.
Cell cycle analysis
Cells were treated with Ad and/or 5-FU, fixed in ice-cold 70% ethanol, incubated with RNase (50 mg ml ) and stained with propidium iodide (50 mg ml À 1 ). The staining profiles were analyzed with FACSCalibur (BD Biosciences) and CellQuest software (BD Biosciences).
Western blot analysis
Cells were treated with Ad and/or 5-FU and the cell lysates were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis. The protein was transferred to a nylon filter and was hybridized with antibody against p53 (Lab Vision, Fremont, CA, USA), phosphorylated p53 at serine (Ser) residues 15, caspase-3, cleaved caspase-3, caspase-8, cleaved caspase-8, caspase-9, cleaved caspase-9, poly (ADP-ribose) polymerase (PARP), cleaved PARP, Beclin-1, Atg5, LC3A/B, Akt, phosphorylated Akt, phosphorylated extracellular signal-regulated protein kinases 1 and 2 (Erk1/2), IkB-a (Cell Signaling, Danvers, MA, USA), MDA-7, MDM2 (Santa Cruz Biotech, Dallas, TX, USA) and GAPDH (Abcam, Cambridge, UK) as a control. The membranes were developed with the ECL system (GE Healthcare, Buckinghamshire, UK).
Half-maximal inhibitory concentration (IC 50 ) and statistical analysis IC 50 was estimated with a program related to nonlinear least squares in FORTRAN77 Version 3.5 developed by Dr Yamaoka (Kyoto University, Kyoto, Japan, http://www.pharm.kyoto-u.ac.jp/byoyaku/Kinetics/program/ manual.htm). Statistical analyses were performed with analysis of variance. Ad-mda-7 with chemotherapy for esophageal cancer G Ma et al all the esophageal carcinoma tested but not the fibroblasts mediated the MDA-7-mediated signaling.
RESULTS
Expression
Ad-mda-7-mediated cytotoxic effects on esophageal carcinoma We examined cytotoxicity of Ad-mda-7 to esophageal carcinoma cells with different amounts of Ad ( Figure 2a ). They were susceptible to Ad-mda-7 but the sensitivity was different among cell types, whereas Ad-LacZ scarcely produced antitumor effects. In contrast, OUMS-24 and HFF cells were resistant to Ad-mda-7 because of deficient receptor complexes. Lung carcinoma A549 cells were reported to be highly susceptible to Ad-mda-7 7 and compared cytotoxic data showed that esophageal carcinoma cells were in general less sensitive to Ad-mda-7 than A549 cells. We confirmed expression of MDA-7 in Ad-mda-7-infected TE-11 and A549 cells, and detected multiple MDA-7 bands as previously reported (Figure 2b) . 7 We also compared cytotoxicity by Ad-mda-7 with that by Ad-p53 in the same esophageal carcinoma cells (Figure 3 ). We found that the cytotoxic effects produced by Ad-p53 were much greater than those by Ad-mda-7. These data suggested that esophageal carcinoma cells were relatively insensitive to Ad-mda-7.
Combinatory cytotoxicity by Ad-mda-7 and anticancer agents We further examined the cytotoxic effects produced by the combination of Ad-mda-7 and an anticancer agent (Figure 4 ). Combinatory treatments with Ad-mda-7 and 5-FU produced greater cytotoxicity than Ad-mda-7 or 5-FU treatments alone in all the esophageal carcinomas tested (Figure 4a ). The combinatory effects were also produced with Ad-mda-7 and CDDP except two cases of TE-1 or T.Tn cells treated with Ad-mda-7 alone (Figure 4b) , with Ad-mda-7 and MMC in all the cells (Figure 4c ) and with Admda-7 and VP-16 except TE-1 cells treated with Ad-mda-7 alone (Figure 4d ). Cytotoxicity by the respective combinations was thus greater than that by Ad-mda-7 treatment in most of the cells and we also compared IC 50 values of the anticancer agents and of the combinatory treatments (Table 1) . We observed improved IC 50 values of 420% in the combinatory treatments compared with treatments with the agent alone in most of the cases, except three cases, that is, VP-16 in TE-1 cells, MMC in YES-6 cells and CDDP in T.Tn cells. These data collectively demonstrated that Ad-mda-7 enhanced the agent-mediated cytotoxicity and the combination produced greater antitumor effects than monotherapy. Ad
Cell cycle changes
We investigated cell cycle changes induced by Ad-mda-7 and the combination with 5-FU in p53 wild-type TE-11 cells ( Figure 5 ). Transduction with Ad-mda-7 augmented G2/M-phase populations and slightly increased sub-G1 fractions on day 3. Similarly, 5-FUtreated cells increased S-phase populations and sub-G1 fractions thereafter. TE-11 cells treated with both Ad-mda-7 and 5-FU showed upregulated sub-G1 fractions greater than those treated with Ad-mda-7 or 5-FU alone, suggesting that the combination increased apoptotic cell death.
Molecular changes induced by the combination of Ad-mda-7 and 5-FU We examined the expression of cell death-and survival-linked molecules to investigate possible mechanisms of the combinatory antitumor effects in TE-11 cells (Figure 6 ). Ad-mda-7 infection induced cleavages of caspase-8, -9, -3 and PARP with decreased levels of respective uncleaved molecules. As for the autophagy pathways, Ad-mda-7-treated cells showed downregulated expression of Beclin-1, but the levels of Atg5 and LC3A/B remained unchanged. TE-11 cells treated with 5-FU slightly increased PARP cleavage but did not show any changes in other caspases or autophagy-linked molecules compared with untreated or AdLacZ-infected cells. The combination of Ad-mda-7 and 5-FU induced caspase-3 cleavage slightly greater than Ad-mda-7 treatments, but the expression levels of cleaved caspase-8, -9 and PARP were not different between Ad-mda-7 and the combination treatments. The combination did not induce any exchanges on the expression levels of autophagy-linked molecules compared with Ad-mda-7 treatments alone. These data suggested that the combination-induced molecular changes were scarcely different from Ad-mda-7-mediated changes.
We also investigated the expression of representative molecules in Akt, Erk, nuclear factor (NF)-kB and the p53 pathways. We examined phosphorylated Erk1/2 as an activation marker for the mitogen-activated protein kinase systems, and IkB-a as an inhibitor for the NF-kB pathways. Transduction with Ad-mda-7 induced Akt phosphorylation with subsequent decrease of Akt levels, and decreased IkB-a, phosphorylated Erk1/2 and p53 levels, whereas MDM2 and phosphorylated p53 at Ser 15 levels remained unchanged. These data suggested that Ad-mda-7 produced mixed reactions as to cell growth signal pathways. Ad-mda-7 treatments augmented cell growth pathways, Akt and NF-kB, but at the same time suppressed growth signals of Erk. In contrast, 5-FU treatments augmented phosphorylated p53 at Ser 15 and to less extent phosphorylated Erk1/2, but decreased IkB-a, Akt and, slightly, the MDM2 levels. Treatments with 5-FU thereby activated the p53 pathways and also induced mixed reactions regarding cell growth signals. Combinatory treatments of Ad-mda-7 and 5-FU showed similar expression levels of these molecules as found in Ad-mda-7 treatments except decreased Akt phosphorylation, and MDA-7 levels remained almost the same between the combination and Ad-mda-7 treatments. The major difference found in the combination was thus decrease of the Ad-mda-7-mediated Akt activation. On the other hand, the comparison with 5-FU treatments indicated that the major alteration in the combination was downregulation of phosphorylation of Erk1/2 and p53, but these phosphorylation levels in the combination were the same as the Ad-mda-7-treated case.
DISCUSSION
We examined the possible antitumor effects of Ad-mda-7 on human esophageal carcinoma cells. Ad-mda-7 produced cytotoxic effects on all the esophageal carcinoma cells but not Ad-mda-7 with chemotherapy for esophageal cancer G Ma et al fibroblasts, and cell cycle analyses of Ad-mda-7-infected cells showed increase of G2/M-phase followed by sub-G1-phase populations. We observed cleavage of caspase-8 and -9 in the infected cells, indicating that Ad-mda-7 induced apoptosis through the extrinsic and the intrinsic pathways. Cytotoxic activities of Ad-mda-7 were not as great as those of Ad-p53 but a combinatory use of Ad-mda-7 and chemotherapeutic agents produced greater cytotoxicity than Ad-mda-7 or the agent alone. The Ad-mda-7-mediated antitumor effects were variable and dependent on cells tested because the cell death mechanisms were subjected to a variety of cellular factors. 5 The present study demonstrated that Ad-mda-7 induced cleavages of caspases and PARP but did not influence expression levels of autophagy-linked molecules except Beclin-1, suggesting that apoptosis played a crucial role in Ad-mda-7-mediated cell death. In contrast to the apoptosis-prone molecular events, we observed increased phosphorylation of Akt and decreased IkB-a, both of which rather favored cell growth. Activation of Akt signaling is often associated with cell cycle progression, and decreased IkB-a results in activation of NF-kB signaling that induces multiple cellular responses including cell survivals. These survival-prone events can be attributable to a feedback mechanism for cells to counteract cell death events. Ad-mda-7 also showed slight decrease of Erk1/2 signaling and p53 expression levels, but their functional roles in cell death could be minimal. In contrast to the present study, previous studies demonstrated that Ad-mda-7 downregulated the Akt pathways [11] [12] [13] and enhanced the Erk1/2 pathways. 14 Nevertheless, Pataer et al. 15 demonstrated that Ad-mda-7 upregulated phosphorylation of Akt but decreased total Akt levels as we observed. This inconsistency in the signal transduction suggested that differential cell signaling systems were activated by Ad-mda-7 in respective cells.
Esophageal carcinoma cells treated with 5-FU showed minimal changes on caspase-9 and PARP cleavages and increased S-phase populations followed by sub-G1 fractions. The treated cells decreased IkB-a expression, increased phosphorylated Erk1/2 levels and, furthermore, augmented p53 phosphorylation with decreased expression in MDM2, a target of the p53 pathways. These data showed complex responses induced by 5-FU treatments but collectively indicated that 5-FU-mediated DNA damages augmented the p53 pathways by way of the phosphorylation and decreased expression of MDM2 that mediated p53 degradation, and that 5-FU-induced inhibition of RNA synthesis stimulated a feedback response that subsequently activated the Erk1/2 and the NF-kB pathways.
We demonstrated a combinatory use of Ad-mda-7 and chemotherapeutic agents, 5-FU, CDDP, MMC or VP-16, each of which directed different cellular pathways. All the agents produced combinatory cytotoxicity with Ad-mda-7 in most of the cells tested, and improved the IC 50 values in the presence of Ad-mda-7 except a few cases. Interestingly, we did not observe significant changes in apoptosis signals between the combination-treated cells and Ad-mda-7-treated cells, although cell cycle analyses showed increased sub-G1 fractions in the combination. Moreover, expression levels of IkB-a and phosphorylated Erk1/2 were scarcely different, and those of MDM2 and phosphorylated p53 were minimally different between the combination and Admda-7 treatments. Expression levels of these molecules in the combination-treated cells were thus similar to those in Ad-mda-7-treated cells but not to those in 5-FU-treated cells. The major change detected between the combination and Ad-mda-7 treatments was downregulation of phosphorylated Akt, but the difference of MDA-7 expression, which could be due to inhibited protein synthesis by 5-FU, was minimal. We presume that enhanced cytotoxicity by the combination was associated with or triggered by inactivation of the Akt pathways.
The Ad-mda-7-mediated antitumor actions need further investigations regarding cell death in the context of p53 and tumor specificity of the cytotoxic effects. The present study showed that sensitivity to Ad-mda-7 was not linked with the endogenous p53 status as demonstrated in other studies, 16 and that Ad-mda-7 did not influence p53 phosphorylation levels although p53 levels were slightly downregulated. In contrast, Kawabe et al. 17 demonstrated that Ad-mda-7 treatments augmented p53 expression despite Admda-7-mediated effects being p53 independent. We showed that Ad-mda-7 induced cleavages of caspases and PARP that suggested that Ad-mda-7 achieved p53-independent cell death with caspase activation.
A precise mechanism underlying tumor specificity of Ad-mda-7-induced cytotoxicity remained uncharacterized. The present study showed that normal fibroblasts did not express the MDA-7/IL-24 receptor complexes, which could be one of the mechanisms for nontoxicity of Ad-mda-7 in untransformed cells. Kreis et al. 18 demonstrated that recombinant MDA-7 protein did not induce apoptosis in melanoma cells, and our preliminary study also indicated that recombinant MDA-7 was not cytotoxic to the esophageal carcinoma cells used in the present study (data not shown) that was contradictory to a previous study that MDA-7 protein induced cell death via the MDA-7/IL-24 receptor complexes. 19 Biological functions and action mechanisms of MDA-7 are thus not yet fully clarified and a number of factors are presumably involved in the machinery that reflects multiple genetic difference of tumors.
The present study is the first report to our knowledge to demonstrate the cytotoxic effects of Ad-mda-7 on esophageal squamous cell carcinoma. A previous study by Pataer et al. 7 used two kinds of human esophageal carcinoma cells and showed the Ad-mda-7-mediated activity, but a subsequent study demonstrated that the two cell lines used were not of esophagus origin. 20 Moreover, there has been only one study, using nasopharygeal carcinoma cells, that demonstrated Ad-mda-7 effects for squamous cell carcinoma among tumors in upper gastrointestinal tracts. 21 A clinical study demonstrated that Ad-mda-7 administration was safe, 22 and a combinatory use of Ad-mda-7 and a chemotherapeutic agent also produced enhanced cytotoxicity. 23, 24 These data suggest feasibility of a clinical study for esophageal carcinoma with Ad-mda-7 in combination of a chemotherapeutic agent and such a clinical investigation can afford a clue to understand a complex mechanism of Ad-mda-7-mediated and the combination-mediated cytotoxicity. Figure 6 . Expression of molecules linked with apoptosis, autophagy and signal transduction. TE-11 cells were treated with adenoviruses expressing human mda-7/IL-24 gene (Ad-mda-7; 10 000 vp per cell) and/or 5-fluorouracil (5-FU; 10 mM) for 2 days and the expression levels were examined with western blot analysis. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is used as a loading control.
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